Skip to main content
Premium Trial:

Request an Annual Quote

Reprogenetics, Illumina Collaborate on NGS-based IVF Technologies

NEW YORK (GenomeWeb) – Preimplantation genetics laboratory Reprogenetics today announced a deal with Illumina as its preferred partner for the development of next-generation sequencing-based in vitro fertilization technologies.

Reprogenetics will expand its current array-based preimplantation genetic screening service to one using Illumina's VeriSeq PGS, a kit that leverages NGS to screen all 24 chromosomes to identify embryos with the greatest potential of producing a viable pregnancy. The Livingston, NJ-based company added that it will lead research collaborations with Illumina to investigate the accuracy of NGS protocols and to conduct randomized clinical trials in subsets of patients who are candidates for comprehensive chromosome screening.

The use of Illumina's technologies will allow Reprogenetics to maximize the potential of NGS-based technologies for preimplantation genetic screening, preimplantation genetic diagnosis, and infertility in its laboratories worldwide, Reprogenetics said.

Financial and other terms of the deal were not disclosed.

"By combining our more than 20 years of expertise in preimplantation screening and diagnosis with Illumina's cutting-edge NGS platform, we have the right tools to deliver breakthroughs that improve the likelihood of positive pregnancy outcomes," Reprogenetics Founder and Director Santiago Munne said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more